digoxin and hydrochlorothiazide

Thiazide diuretics such as hydrochlorothiazide increase renal potassium excretion, leading to hypokalemia. Hypokalemia increases the sensitivity of the myocardium to digoxin by reducing the activity of the sodium-potassium ATPase, which is the target of digoxin. This enhances digoxin binding and reduces the therapeutic index. Additionally, volume depletion from diuresis may reduce renal clearance of digoxin, further increasing serum digoxin concentrations. The interaction is primarily pharmacodynamic via electrolyte disturbance, with a potential pharmacokinetic component.

Hypokalemia can precipitate digoxin toxicity at normal or even sub-therapeutic digoxin concentrations, manifesting as cardiac arrhythmias (e.g., ventricular ectopy, atrial tachycardia with block), gastrointestinal symptoms (nausea, vomiting), and neurological effects (visual disturbances, confusion). The risk is highest when potassium is low, particularly below 3.0 mmol/L. Patients taking both drugs require careful monitoring, as the combination is commonly used in heart failure and hypertension.

Monitor serum potassium and renal function at baseline, within 1-2 weeks after starting or changing doses, and periodically thereafter. Consider potassium supplementation or use of potassium-sparing diuretics if hypokalemia develops. Adjust digoxin dose if renal function deteriorates. In patients with concurrent hypokalemia, correct the potassium deficit and reassess digoxin levels. Consider digoxin level monitoring in patients with symptoms of toxicity or if potassium is persistently low.

Well-established and widely recognized. Numerous studies and clinical guidelines highlight the risk of hypokalemia-induced digoxin toxicity with thiazide diuretics. The interaction is a standard consideration in clinical practice and is included in major drug interaction compendia and package inserts. The mechanism is well understood and the clinical consequences are documented.